ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside
B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.
C&EN3d
Medicinal Chemistry: A Key Driver in Achieving the Global Sustainable Development Goals
Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. In 2015, the United Nations officially launched the Sustainable Development Goals ...